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Urothelial bladder cancer represents a heterogeneous disease with divergent pathways of tumorigenesis. Tumor invasion and
progression are a multifactorial process promoted by microenvironmental changes that include overexpression of matrix
metalloproteinases (MMPs). Recent data clearly challenge the classic dogma that MMPs promote metastasis only by modulating
the remodeling of extracellular matrix. Indeed, MMPs have also been attributed as an impact on tumor cell behavior in vivo as
a consequence of their ability to cleave growth factors, cell surface receptors, cell adhesion molecules, and chemokines/cytokines.
Levels of the different MMPs can be measured in several sample types, including tissue, blood (serum and plasma), and urine,
and using different methodologies, such as immunohistochemistry, real-time PCR, western and northern blot analyses, enzyme-
linked immunosorbent assay, and zymography. Several MMPs have been identified as having potential diagnostic or prognostic
utility, whether alone or in combination with cytology. Although MMP inhibitors have shown limited efficacy, advances in the
understanding of the complex physiologic and pathologic roles of MMPs might permit the development of new MMP-specific and
tumor-specific therapies. In this paper we update the understanding of MMPs based on a systematic PubMed search encompassing
papers published up to December 2011.
1. Introduction
Urothelial bladder carcinoma (UBC) represents a heteroge-
neous disease with high morbidity and mortality. It ranks
fifth among all cancers in the Western world, and there are
336,000 new cases and 132,000 deaths annually worldwide
[1]. UBC mainly affects the elderly, with the peak incidence
occurring after the age of 50. It is more common in males,
in white people, and in developing countries. Most cases are
sporadic, so a familial history is lacking. Cigarette smoking
is a major risk factor. Other risk factors include exposure
to arylamines, radiotherapy to adjacent organs, alkylating
chemotherapeutic agents, and chronic inflammation [2].
There are two theories regarding the multifocal nature of
urothelial carcinoma: “field cancerization” and “monoclon-
ality” [3]. Genetic studies support the monoclonality theory
and indicate that tumor cells spread from their origins
to multiple sites by intraepithelial or intraluminal seeding.
Non-muscle-invasive (NMI) disease accounts for ca. 70% of
cases. Despite treatment with BCG, high-grade NMI tumors
are associated with a high risk of recurrence and progression.
Approximately 20% of primary diagnosed UBCs are muscle
invasive. Platinum-based chemotherapy remains the treat-
ment of first choice in neoadjuvant, adjuvant, and metastatic
disease. However, ultimately disease recurs in most patients
and life expectancy after recurrence is limited. Current clini-
cal and pathologic predictive factors (stage, grade, associated
carcinoma in situ (CIS), lymph node status, multiplicity, sex)
are insufficient to predict prognosis [4]. Efforts are focusing
on the study of the urothelial tumorigenesis and the develop-
ment of new biomarkers with prognostic and predictive util-
ity. Moreover, UBC is one of the few tumors where the direct
administration of therapeutic drugs to the tumoral cells is
feasible via the intravesical route, offering the maximum
local drug concentration and minimum systemic toxicity.
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2. Urothelial Tumorigenesis
Urothelial tumors arise and evolve through divergent pheno-
typic pathways. Less aggressive tumors range from urothelial
hyperplasia to low-grade NMI papillary tumors. The latter
low-grade variant is often multifocal and presents high rates
of recurrence. More aggressive variants either arise from
high-grade and flat lesions of CIS and progress to become
invasive tumors or initially develop as invasive tumors. Des-
pite BCG or cystectomy, metastases often develop [5].
The low-grade NMI variant is characterized by activation
of mutations in the HRAS gene and the fibroblast growth fac-
tor receptor 3 gene [6]. High-grade and invasive tumors are
characterized by structural and functional defects in the p53
and retinoblastoma protein (RB) tumor suppressor path-
ways [7]. Deletion of both arms of chromosome 9 is preva-
lent in urothelial carcinomas and occurs during the earliest
stages of tumorigenesis; however, the genetic alterations in
chromosome 9 do not seem to distinguish between the two
tumor development pathways [8].
Tumor invasion and progression in the bladder represent
a multifactorial process promoted by microenvironmental
changes that include upregulation of N-cadherin, downreg-
ulation of E-cadherin, overexpression of matrix metallopro-
teinases (MMP) 2 and 9, imbalance between angiogenic
and antiangiogenic factors, and increased synthesis of pro-
staglandin.
3. Matrix Metalloproteinases
Levels of the different MMPs can be measured in several
sample types, including paraffin-embedded or fresh-frozen
tissue, serum, plasma, and urine, and by various analytical
methodologies, such as immunohistochemistry, real-time
PCR, western and northern blot analyses, enzyme-linked
immunosorbent assay, and zymography. Several MMPs have
been identified as having potential diagnostic or prognostic
utility, whether alone or in combination with currently
available diagnostic tests or imaging modalities. Although
the early broad-spectrum anti-MMP agents showed a lack
of efficacy, our continually improving understanding of the
complex physiologic and pathologic roles of MMPs might
enable the development of new MMP-specific and tumor-
specific therapies.
3.1. Classification and Structure. MMPs are a large family—
there are at least 26 human MMPs—of calcium-dependent
zinc-containing endopeptidases, which are responsible for
the tissue remodeling and degradation of proteins of the
extracellular matrix (ECM), including collagens, elastins,
gelatin, matrix glycoproteins, and proteoglycans. On the
basis of their specificity, MMPs are classified into collage-
nases, gelatinases, stromelysins, and matrilysins.
Another subclass of MMPs is represented by the
membrane-type MMPs (MT-MMPs), which contain a trans-
membrane and an intracellular domain a membrane linker
domain or are membrane associated [9] (Table 1).
The exact domain organization, polypeptide fold, and
main specificity determinants are provided by the crystal
structures of MMPs [10]. Most MMPs are composed of
several distinct domains: an N-terminal prodomain (also
termed propeptide), a catalytic domain (MMP-7 and MMP-
26), and a hemopexin-like C-terminal domain connected
by a linker or hinge region (MMP-1, MMP-3, MMP-8,
MMP-11, MMP-12, MMP-13, MMP-18, MMP-19, MMP-
20, MMP-21, MMP-27, and MMP-28). Others additionally
have a fibronectin-like domain (MMP-2 and MMP-9), a
transmembrane region (MMP-14, MMP-15, MMP-16, and
MMP-24), or a glycosylphosphatidyl anchor (MMP-17 and
MMP-25) [11]. The N-terminal prodomain contains in
its motif PRCGXPD, a cysteine residue which interacts
with the catalytic domain, preserving the MMP inactivity.
The catalytic domain, sequence motif HEXGHXXGXXH,
contains three histidine residues which ligate the zinc ion
and the glutamic acid residue, facilitating catalysis. The cat-
alytic domain additionally contains a conserved methionine,
forming a “Met-turn” eight residues after the zinc binding
motif, which forms a base to support the structure around
the catalytic zinc. The zinc binding motif and the Met-turn
are conserved in members of the ADAM (a disintegrin and
metalloproteinase) family and the ADAMTS (ADAM with
thrombospondin motifs) family [12].
3.2. Activation. MMPs can be activated in vitro by several
mechanisms, including mercurial compounds, SH reagents,
chaotropic agents, and other proteases [13]. This property is
used to activate proMMPs in the laboratory. The N-termin-
al prodomain maintains MMPs in their zymogen form
(proMMPs); these zymogens are then processed by other
proteolytic enzymes, such as serine proteases or plasmin, to
generate the active forms. Thirteen mammalian MMPs are
secreted from the cell as proMMPs. The propeptide contains
a “bait” region for proteinase that allows proMMP activation
by tissue and plasma proteinases. Cleavage of the bait region
removes only a part of the propeptide, and complete removal
of the propeptide is often conducted in trans by the action
of the MMP intermediate or by other active MMPs. This is
the mechanism termed “stepwise activation” [14]. A furin-
like proprotein convertase recognition sequence, RX[K/R]R,
is present at the end of the propeptide in ten proMMPs.
These proMMPs may be activated intracellularly, cell surface
bound, or secreted [15].
3.3. Inhibitors. MMP activities are regulated by two major
types of endogenous inhibitor: α2-macroglobulin and tissue
inhibitors of MMPs (TIMPs). Human α2-macroglobulin is
a plasma glycoprotein of 725 kDa consisting of four iden-
tical subunits of 180 kDa. It inhibits most proteinases by
entrapping the proteinase within the macroglobulin, and the
complex is rapidly cleared by receptor-mediated endocytosis
[16]. TIMPs are a family comprising four members (TIMP-
1, -2, -3, and -4). They consist of 184–194 amino acids
subdivided into an N-terminal and a C-terminal subdo-
main.
Each domain contains three conserved disulfide bonds
and the N-terminal domain folds as an independent unit
with MMP-inhibitory activity. TIMPs inhibit all MMPs
tested so far; however, TIMP-1 is a poor inhibitor for
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Table 1: Human matrix metalloproteinases (MMPs).




1 MMP-1 Collagenases Collagenase-1
57∗
47 A








Collagens (I, II, III, VII, VIII, and X), fibronectin,
proteoglycans
3 MMP-13 Collagenases Collagenase-3
60∗
48 A
Collagens (I, II, III, VII, VIII, and X), tenascin, plas-
minogen, aggrecan, fibronectin, osteonectin, MMP-9




5 MMP-2 Gelatinases Gelatinase-A
72∗
66 A
Gelatin, collagen (IV, V, VII VI, IX, and X), elastin,
fibronectin
6 MMP-9 Gelatinases Gelatinase-A
92∗
86 A
Collagens (IV, V, VII, X, and XIV), gelatin, entactin,
elastin, fibronectin, osteonectin, plasminogen,
proteoglycans
7 MMP-3 Stromelysins Stromelysin-I
60∗
52 A
Collagens (IV, V, and IX), gelatin, aggrecan, laminin,
elastin, casein, osteonectin, fibronectin, ovostatin,
entactin, plasminogen
8 MMP-10 Stromelysins Stromelysin-2
53∗
47 A
Collagens (I, II, IV, and V), gelatin, casein, elastin,
fibronectin
9 MMP-11 Stromelysins Stromelysin-2
60∗
47 A








11 MMP-7 Matrisylins Matrisylin
28∗
19 A
Collagen IV, gelatin, fibronectin, laminin, elastin, casein,
transferrin








Collagens (I, II, III), gelatin, fibronectin, laminin,
vitronectin, entactin, pro-MMP-2
14 MMP-15 MT-MMP MT2-MMP 76
Fibronectin, gelatin, vitronectin, entactin, laminin, pro-
MMP-2
15 MMP-16 MT-MMP MT3-MMP
65∗
63 A
Collagen III, gelatin, casein, fibronectin, pro-MMP-2




17 MMP-24 MT-MMP MT5-MMP 73 Fibronectin, pro-MMP-2, proteoglycans, gelatin
18 MMP-25 MT-MMP MT6-MMP 62
Pro-MMP-2, pro-MMP-9, collagen IV, gelatin, fibro-
nectin, proteinase A





Collagen IV, gelatin, elastin, casein, fibronectin, vit-
ronectin, laminin, entactin, fibrin/fibrinogen
20 MMP-19 Other enzymes RASI I 59 Collagen (I, IV) gelatin, fibronectin, laminin
21 MMP-20 Other enzymes Enamelysin 56 Amelogenin, aggrecan
22 MMP-21 Other enzymes 65
23 MMP-22 Other enzymes
58∗
53 A
24 MMP-23 Other enzymes 44 Gelatin
25 MMP-27 Other enzymes 59
26 MMP-28 Other enzymes Epilysin 59
∗Zymogen molecular weight; A: active form molecular weight.
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MT1-MMP, MT3-MMP, MT5-MMP, and MMP-19. TIMP-
3 has been shown to inhibit members of both the ADAM
family (ADAM-10, -12, and -17) and the ADAMTS family
(ADAMTS-1, -4, and -5). In addition, TIMP-1 inhibits
ADAM-10. Crystal structures of the TIMP-MMP complexes
have been shown to be central to the mechanism of TIMP
inhibition of MMPs [17, 18]. TIMPs have four N-terminal
residues that are linked by a slot into the active site of the
MMPs. This region accounts for about 75% of the protein–
protein interaction in the case of the complex of the catalytic
domain of MMP-3 and TIMP-1. TIMP concentrations gen-
erally far exceed the concentration of MMPs in tissue and
extracellular fluids, thereby limiting the proteolytic activity
of MMPs to focal pericellular sites. In contrast to the usual
inhibitory role of TIMPs, a low concentration of TIMP-2
enhances MMP-14-induced activation of MMP-2 by forming
a triplex with these proteins on the cell surface [19]. In
addition, TIMPs have been shown to have growth-promoting
activities which are independent of their MMP inhibitory
function and apoptosis-inducing properties (TIMP3). The
transcription of TIMPs is regulated by cytokines and growth
factors similar to those that control MMP expression,
although often in distinctive ways.
3.3.1. S1′ Specificity Loop Inhibitor. Differences in MMP
active sites reside in specificity loop residues that form the S1′
subsite pocket. This leads to structural and chemical differ-
ences in the S1′ subsite that are reflected in the substrate
preferences of the shallow pocket MMPs (1 and 7) compared
with deep pocket MMPs (2, 3, 8, 9, 12, and 13) [20]. The
development of novel specific inhibitors for MMP-12 and
MMP-13 is attributable to differences in the S1′ pocket. An
additional small region termed the “S1′ side-pocket” was
used to specifically target MMP-13. The success of these inhi-
bitors clearly demonstrates the benefits of good mechanistic
and structural information for inhibitor design.
3.3.2. Zinc-Binding Group Inhibitors. Zn2+-chelating hydrox-
amates have been favored in MMP inhibitor design. How-
ever, in some cases they overwhelm the contribution from
the rest of the compound, reducing opportunities for im-
proved specificity. Indeed, hydroxamate activity-based MMP
probes bind many off-target metalloproteases outside the
MMP family. The use of union to Zn2+ ion seems to require
an improvement in specificity.
3.3.3. Covalent Inhibitors. Upon binding, these inhibitors
covalently modify residues in the active site of the enzyme.
Since the reactive species is formed only within the active
site of the targeted enzyme, it provides high specificity and
in vivo selectivity. Thiirane sulfur-containing anti-MMP-2
and -9 inhibitor forms a reversible covalent bond with the
active site glutamate and was found to exert a great effect in
an aggressive murine model of T-cell lymphoma [21]. The
development of noncovalent inhibitors is preferred due to
the low risk of side-effects. Exosite binding and allosteric
inhibitors also seem to be more promising [22].
3.4. Functions. The main function of MMPs is to degrade
structural components of the ECM. However, MMP prote-
olysis can create space for cell migration, produce specific
substrate-cleavage fragments with independent biological
activity, regulate tissue architecture through effects on the
ECM and intercellular junctions, and modify the activity
of signaling molecules, both directly and indirectly [23].
Also, MMPs can affect cellular functions by regulating the
ECM proteins with which the cells interact. The collagenases
MMP-1, MMP-8, MMP-13, and MMP-14 are the only MMPs
that can efficiently degrade the fibrillar collagens (types I,
II, and III) in their triple-helical domains [24]. Cleavage
by these enzymes renders the collagen molecules thermally
unstable, so that they unwind to form gelatin, after which
they can be degraded by other members of the MMP family
such as the major gelatinases, MMP-2, and MMP-9. These
two major gelatinases have several distinctive features. They
can be distinguished by the fact that MMP-2 binds preferen-
tially to TIMP-2, which is required for its activation, whereas
MMP-9 is preferentially inhibited by TIMP-1 [25]. MMP
substrates include peptide growth factors, tyrosine kinase
receptors, cell adhesion molecules, cytokines, chemokines, as
well as other MMPs and unrelated proteases. Furthermore,
MMPs can participate in several other biological processes
such as angiogenesis. Angiogenesis is a complex multistep
process defined as the formation of new blood vessels from
existing endothelial-lined vessels. This is distinct from the
process of vasculogenesis in a way that the endothelial
cells arise by proliferation from existing vessels rather than
through differentiation from stem cells. Angiogenesis is an
invasive process that requires proteolysis of the ECM and
proliferation and migration of endothelial cells, as well as
synthesis of new matrix components. Understanding the
circumstances under which MMP activity is involved in the
angiogenic phenotype has important implications for can-
cer therapy because angiogenesis is necessary for tumor
growth and metastasis. It has been reported that MMP-2,
MMP-9, and MT1-MMP released by endothelial cells are
induced by vascular endothelial growth factor (VEFG) and
basic fibroblast growth factor (bFGF), which are known to
be potent mitogens and chemoattractants [26].
However, some MMP degradation products of ECM are
antiangiogenic [27]. In summary, MMPs could have a double
effect on angiogenesis. Programmed cell death, commonly
termed apoptosis, is a very well ordered process by which
unwanted, defective, or damaged cells are rapidly and selec-
tively eliminated from the body. MMPs play an intriguing
role in apoptosis, showing both apoptotic and antiapoptotic
actions [28]. MMPs affect cell survival and proliferation both
positively and negatively by regulating “survival signals”;
these particular effects of MMPs may reflect the differences in
MMP substrates involved in each response [29–31]. MMP-7
is able to release membrane-bound Fas ligand (FasL), which
induces apoptosis of neighboring cells or decreases cancer
cell apoptosis, depending on the system [32, 33]. Moreover,
the cleavage of pro-heparin-binding epidermal growth factor
(pro-HB-EGF) by MMP-7 leads to a biologically active HB-
EGF that promotes cell survival by stimulating the erb-
B4 receptor tyrosine kinase [34]. Other MMPs, such as
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MMP-11 and MMP-3, have a pro- or antiapoptotic effect
depending on the circumstances [35–39]. The proapoptotic
effect of MMP-2 and MMP-9 has been described during tis-
sue remodeling and neoangiogenesis [40].
3.5. Analytical Methods. Several analytical methods can be
used to measure MMPs, the choice of technique depending
on the aim of the analysis. Here, we present the most widely
used techniques. Zymography can be used to determine
protease activity in both tissue homogenates and body fluids.
Zymography and reverse zymography are simple, sensitive,
quantifiable, and functional assays to analyze MMPs and
TIMPs in biological samples [40]. Zymography is based on
the following principles: retention of the substrate in the gel
during electrophoresis, reversible inhibition of MMP activity
by SDS during electrophoresis, and separation of MMP-
TIMP complexes caused by SDS during electrophoresis.
Zymography permits distinction of both proenzymes and
active forms of MMPs based on their molecular weight
[41, 42]. Several techniques can be used to determine MMP
expression independently of zymogen or active form. First,
western blot is a commonly used method in molecular biol-
ogy to detect a target protein in a sample, containing a com-
plex mixture of proteins, by using a polyclonal or mono-
clonal antibody specific to that protein. This technique is
similar to zymography except that the gel does not contain
substrate. Another technique is the enzyme-linked immuno-
sorbent assay (ELISA). ELISA is a biochemical technique
mainly used in immunology; the classical ELISA used for the
detection of MMP is the sandwich ELISA. Specific antibodies
to target protein are precoated onto 96-well plates. The test
sample, body fluid or cell protein extract, is added to the
wells [42]. Immunochemistry is another technique widely
used for MMP detection. Serial sections are consecutively
cut from formalin-fixed and paraffin-embedded tissue blocks
using a microtome and are then transferred to adhesive-
coated slides. This technique allows the determination of
MMP localization and MMP producer cell type and a semi-
quantitative determination. Finally, polymerase chain reac-
tion (PCR) can be used. As the name implies, this technique
involves a chain reaction: one DNA molecule is used to
produce two copies, then four, then eight, and so forth.
This continuous doubling is accomplished by specific
proteins known as polymerases, enzymes that are able to
string together individual DNA building blocks to form long
molecular strands [42].
4. MMPs in Bladder Cancer
Some of the best candidates for a biological marker in blad-
der cancer are the MMPs, which have a well-known role in
the degradation of connective tissue stroma and basement
membranes (key barriers to tumor progression), promoting
invasion, immune escape, and many other events.
In addition, recent data clearly challenge the classic
dogma that MMPs promote metastasis only by modulating
the remodeling of ECM. In fact, MMPs have also been attri-
buted as an impact on tumor cell behavior in vivo as
a consequence of their ability to cleave growth factors,
cell surface receptors, cell adhesion molecules, and chemo-
kines/cytokines [23, 29]. Furthermore, by cleaving proapop-
totic factors, MMPs are able to produce an aggressive phe-
notype by generating apoptosis-resistant cells [43]. MMPs
may also regulate angiogenesis in cancer, both positively
through their ability to mobilize or activate proangiogenic
factors [44] and negatively via generation of angiogenesis
inhibitors, such as angiostatin and endostatin, which are
cleaved from large protein precursors [45]. Consequently,
several MMPs, in particular the gelatinases MMP-2 and
MMP-9, have been widely studied. Conflicting results have
been reported regarding the predictive value of MMP-2 and
MMP-9 in bladder cancer. In this respect, it has to be borne
in mind that studies may not be comparable since they may
differ with respect to stage and grade of disease, blood (serum
or plasma) and tissue sampling, and MMP levels in urine.
Results in urine indicate that urine analyses are more useful
for detection of progression and invasiveness than for early
diagnosis, for which their sensitivity is even lower than that
of urine cytology [46]. MMP-9 activities in urine samples
have provided evidence that the use of MMP-9 as a screening
or diagnostic marker should be explored, as its specificity
appears comparable to that of urinary cytology [46, 47].
MMP-3 has no diagnostic significance and its prognostic
utility is controversial [48, 49]. MMP-7 has shown prognostic
relevance independent of the method of detection used [50].
MMP-14 is mostly expressed in stromal cells and can cor-
relate with stage, grade, and prognosis [51]. The roles of
MMP-10, MMP-11, MMP-13, and MMP-15 in bladder can-
cer have not been widely studied, but MMP-13 revealed
higher expression in tumors with a higher stage and grade
[52]. Decreased concentrations of TIMP-1 in plasma and
increased concentrations in urine have been reported in
bladder cancer [48, 53]. In the case of TIMP-2, two studies
analyzing serum and plasma levels reported higher serum
and plasma concentrations in controls than in bladder cancer
patients [10, 54].
4.1. Tissue-Based Biomarkers. Davies et al. [55] reported that
MMP-2 and MMP-9 activities quantified by gelatin zymo-
graphy were correlated with tumor grade and invasion.
Grignon et al. [56] showed that high levels of TIMP-2 expres-
sion are associated with poor outcome in cystectomy.
Kanayama et al. [51] evaluated MMP-2, TIMP-2, and
MT1-MMP in bladder cancer tissue using RT-PCR and
found MMP-2 and TIMP-2 expression levels to be strongly
associated with tumor stage and prognosis; MT1-MMP
expression, however, was directly correlated with distant
metastasis but not with tumor invasion.
MMP-2 activity as determined by zymography has shown
a strong correlation with tumor invasion. Papathoma et al.
[57] reported that zymographic analysis of MMP-2 and
MMP-9 showed a significant increase in levels with tumor
grade and invasiveness, but the correlation between the
levels of the two gelatinases with recurrence in NMI tumors
was not significant. Ozdemir et al. [58] reported a strong
correlation of basement membrane degradation with p53
inactivation and/or MDM2 overexpression in NMI urothe-
lial carcinomas and suggested that MMP-9 plays a key role
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Table 2: Correlation between MMP levels and clinicopathologic parameters. NA: not available; T: tissue; B: blood; U: urine.
Author B/T/U Pat/Con Method Expres.tm Stage Grade Recurrence Prognosis MMP-
Gohji et al. [4] B 146/52 Enzyme assay Increased NA NA Yes NA
MMP-2
MMP-3




Szarvas et al. [50] B 97/22 Enzyme assay Increased NA NA NA Yes MMP-7





Tasci et al. [67] B 102/94
PCR
lymphocytes
Increased Increased Increased NA NA MMP-1
Offersen et al. [68] U 188/—
Immunocapture
activity assay
Increased Increased Increased Yes Yes MMP-9
Szarvas et al. [69] U 132/96 Enzyme assay Increased NA NA NA Yes MMP-7
Hoque et al. [70] U 175 RT-PCR Methylation Increased NA NA Yes TIMP-3
Eissa et al. [71] U 136/60
ELISA Gelatin
zymography




Di Carlo et al. [73] U 25/—
Gelatin
zymography
Increased Increased Increased NA NA MMP-9
Davies et al. [55] T 42/7 In situ hybrid Increased Increased NA NA Yes
MMP-2
MMP-9
Grignon et al. [56] T 42/— IHQ Increased Increased NA NA Yes TIMP-2
Kanayama et al. [51] T 41/— RT-PCR Increased Increased NA NA Yes
MMP-2
TIMP-2




NA NA NA NA Yes
MMP-2
MMP-9
Hara et al. [61] T 51
Northern blot
analysis
NA Increased Increased Yes NA
MMP-9
TIMP-2
in the invasion step of NMI tumors. Kitagawa et al. [59]
reported that MT1-MMP and MT2-MMP may play an
important role in multifocality. Mohammad et al. [60], in
a zymographic analysis in tissue samples, observed MMP-
2 activity and MT2-MMP expression to be associated with
tumor stage. Hara et al. [61] determined the expression levels
of MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mes-
senger mRNA in UBC specimens using northern blot analy-
sis. Results were evaluated in regard to tumor recurrence and
indicated that MMP-9 and TIMP-2 were strongly expressed
in tumors that displayed recurrence compared with those
that did not. Vasala et al. [54] determined MMP-2 with
a monoclonal antibody for MMP-2 by semiquantitative
immunohistochemical staining of paraffin-embedded tissue.
The results demonstrated that MMP-2 protein overexpres-
sion may be an independent prognostic biomarker for blad-
der cancer progression (Table 2).
4.2. Blood-Based Biomarkers. Blood is a good medium for
analysis of markers for screening and detection purposes
and can also be used for evaluation of prognostic markers.
Advantages over tissue are that blood sampling is minimally
invasive and provides information before surgery. However,
blood sampling methods can strongly affect MMP mea-
surements. Significantly lower MMP-1, MMP-2, and MMP-
7 levels have been found in EDTA-treated plasma samples
compared with citrate-stabilized or heparin-treated plasma.
Also, MMP-8 and MMP-9 showed significantly higher serum
concentrations when collected in tubes with clot activator
than when collected in tubes without such activator. Gohji
et al. reported the prognostic significance of serum MMPs
and TIMPs and the value of imbalance between serum MMP-
2 and its inhibitor as a predictor of recurrence [4, 62–64].
Angulo et al. [65] used RT-PCR to analyze circulating blood
cells for MMP-2, MMP-9, and TIMP-2, and revealed that
MMP-9 has a higher ability to distinguish metastatic disease
but that MMP-2 is better at discriminating levels of tumor
invasion [8]. Szarvas et al. [66] analyzed MMP-7 in serum
using ELISA and concluded that circulating MMP-7 levels
may help to identify bladder cancer patients at high risk
of disease progression. Vasala et al. [10, 54], using ELISA,
determined that high serum levels of circulating pro-MMP-
2 and TIMP-2 are associated with a better clinical course;
moreover, total pro-MMP-2 was found to be an independent
prognostic marker of bladder cancer progression. Tasci
et al. [67] analyzed genomic DNA extracted from peripheral
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blood lymphocytes. Their results suggested that the MMP-
1 promoter polymorphism might be linked to susceptibility
for bladder cancer (Table 2).
4.3. Urine Biomarkers. In patients with bladder cancer, urine
is a particularly useful medium to detect tumor markers
owing to its enhanced potential to contain high concentra-
tions of tumor-derived proteins. Recent data have also shown
that elevated urinary MMP levels and activity correlate with
the presence of different cancers located outside the urinary
tract [13].
Offersen et al. found MMP-9 [68] measured in urine
from bladder cancer patients to be a strong independent
prognostic marker of poor survival. Szarvas et al. [69]
determined the presence of MMP-7 in the urine of patients
with bladder cancer using immunoprecipitation followed by
western blot analysis and observed that MMP-7 could help
to detect metastatic disease. Hoque et al. [70] examined
urine sediment DNA for aberrant methylation of nine genes,
including TIMP-3, by quantitative fluorogenic RT-PCR.
Results suggested that TIMP-3 promoter methylation could
be a clinically applicable marker for bladder cancer progres-
sion. Eissa et al. obtained urine samples and used urine
sediment for cytology and the supernatant for estimation of
MMPs and TIMP-2 by ELISA and gelatin zymography. Com-
bined testing of cytology with these methods improved the
sensitivity of bladder cancer detection, even in superficial and
low-grade tumors [71]. Holten-Andersen et al. [72] assessed
the potential use of TIMP-1 levels in plasma and urine. The
results revealed that the measurement of TIMP-1 in plasma
and/or urine was apparently not useful for the identification
of bladder cancer. Finally, Di Carlo et al. used zymography
to analyze MMP-2 and MMP-9 in urine [73] and observed
that the urinary values of these two biomarkers correlat-
ed with the increase in MMP-9 lytic activity in high-grade
and advanced-stage bladder cancer (Table 2).
5. Conclusions
Bladder cancer represents the most common tumor of the
urinary tract. The prognosis of the tumors diagnosed at
an early stage is excellent, emphasizing the importance of
early diagnosis. Measurements of MMPs in urine, especially
MMP-2 and MMP-9, show a superior diagnostic perfor-
mance compared with cytology but are less sensitive than
determination of other diagnostic markers such as NMP-22.
MMPs could be useful when used in combination with other
methods rather than alone. The need for lifelong surveillance
makes bladder cancer one of the most expensive cancers;
thus MMPs are needed to allow the identification of patients
at risk of recurrence. Urinary MMP-9 levels, serum MMP-
7 levels, and tissue levels of MMP-2, MMP-7, and MMP-14
have been identified as prognostic markers of bladder cancer.
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